In the last trading session, 0.93 million Regulus Therapeutics Inc. (NASDAQ:RGLS) shares changed hands as the company’s beta touched 2.20. With the company’s per share price at $0.84 changed hands at $0.03 or 3.14% during last session, the market valuation stood at $70.67M. RGLS’s last price was a discount, traded about -176.19% off its 52-week high of $2.32. The share price had its 52-week low at $0.45, which suggests the last value was 46.43% up since then. When we look at Regulus Therapeutics Inc.’s average trading volume, we note the 10-day average is 0.85 million shares, with the 3-month average coming to 3.01 million.
Analysts gave the Regulus Therapeutics Inc. (RGLS) stock a consensus recommendation rating of an Overweight, calculated at a mean rating of 2.70. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended RGLS as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Regulus Therapeutics Inc.’s EPS for the current quarter is expected to be -$0.08.
3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Instantly RGLS was in green as seen at the end of in last trading. With action -0.89%, the performance over the past five days has been red. The jump to weekly highs of 0.8522 on Friday, 09/10/21 added 3.14% to the stock’s daily price. The company’s shares are showing year-to-date downside of -37.96%, with the 5-day performance at -0.89% in the red. However, in the 30-day time frame, Regulus Therapeutics Inc. (NASDAQ:RGLS) is 18.64% up. Looking at the short shares, we see there were 5.91 million shares sold at short interest cover period of 4.85 days.
The consensus price target for the stock as assigned by Wall Street analysts is $1.38, meaning bulls need an upside of 39.13% from its current market value. According to analyst projections, RGLS’s forecast low is $0.50 with $2.00 as the target high. To hit the forecast high, the stock’s price needs a -138.1% plunge from its current level, while the stock would need to tank 40.48% for it to hit the projected low.
Regulus Therapeutics Inc. (RGLS) estimates and forecasts
Data shows that the Regulus Therapeutics Inc. share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -57.27% over the past 6 months, a 33.33% in annual growth rate that is considerably higher than the industry average of 18.20%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2021 revenue estimates. The rating firms predict current quarter revenue for Regulus Therapeutics Inc. will rise 65.20%, while the growth in revenue is estimated to hit -100.00% for the next quarter. Year-over-year growth is forecast to reach -99.90% down from the last financial year.
Consensus estimates given by 3 financial analysts project the company’s revenue in the current quarter to hit an average of $10k. 3 analysts are of the opinion that Regulus Therapeutics Inc.’s revenue for the quarter ending Sep 2021 will be $10k. The estimates for the next quarter sales put growth at -97.10%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 49.00%. The 2021 estimates are for Regulus Therapeutics Inc. earnings to increase by 58.20%, but the outlook for the next 5-year period is at 39.60% per year.
Regulus Therapeutics Inc. is expected to release its next quarterly earnings report between November 03 and November 08.
Regulus Therapeutics Inc. (NASDAQ:RGLS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 4.95% of Regulus Therapeutics Inc. shares while 49.70% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 52.29%. There are 49.70% institutions holding the Regulus Therapeutics Inc. stock share, with NEA Management Company, LLC the top institutional holder. As of Mar 30, 2021, the company held 8.62% of the shares, roughly 6.45 million RGLS shares worth $10.06 million.
Vanguard Group, Inc. (The) holds the second largest percentage of outstanding shares, with 4.30% or 3.22 million shares worth $5.02 million as of Mar 30, 2021.
Among Mutual Funds, the top two as of Jan 30, 2021 were USAA Mutual Fund Tr-Science & Technology Fund and Victory Portfolios-Victory RS Science & Technology Fund. With 6.27 million shares estimated at $8.72 million under it, the former controlled 8.38% of total outstanding shares. On the other hand, Victory Portfolios-Victory RS Science & Technology Fund held about 4.13% of the shares, roughly 3.09 million shares worth around $4.83 million.